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In vivo suppression of the renal Na+/Pi cotransporter by
antisense oligonucleotides
Abstract
A 20-mer phosphorothioate oligonucleotide (AS1) was designed to hybridize to the message for the rat
kidney sodium phosphate cotransporter NaPi-2 close to the translation initiation site. Single intravenous
doses of this oligonucleotide were given to rats maintained on a low phosphorus diet to increase NaPi-2
expression. At 3 days after oligonucleotide infusion, rats receiving 2.5 micromol of AS1 exhibited a
reduction in renal NaPi-2 to cyclophilin mRNA ratio by 40% +/- 17%, and rats receiving 7.5 micromol
of AS1 exhibited a reduction in NaPi-2 to cyclophilin mRNA ratio by 46% +/- 21%. Reversed-sequence
AS1 was without effect. The higher dose of 7.5 micromol of AS1 also reduced the rate of phosphate
uptake into renal brush border membrane vesicles and the expression of NaPi-2 protein detected by
Western blotting in these vesicles. Reversed sequence AS1 was again without effect on these
parameters. These results suggest that systemically infused oligonucleotides can exert antisense effects
in the renal proximal tubule.
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ABSTRACT A 20-mer phosphorothioate oligonucleotide
(AS1) was designed to hybridize to the message for the rat
kidney sodium phosphate cotransporter NaPi-2 close to the
translation initiation site. Single intravenous doses of this
oligonucleotide were given to rats maintained on a low phos-
phorus diet to increase NaPi-2 expression. At 3 days after
oligonucleotide infusion, rats receiving 2.5 ,umol of AS1 ex-
hibited a reduction in renal NaPi-2 to cyclophilin mRNA ratio
by 40% ± 17%, and rats receiving 7.5 ,umol of AS1 exhibited
a reduction in NaPi-2 to cyclophilin mRNA ratio by 46% +
21%. Reversed-sequence ASI was without effect. The higher
dose of 7.5 ,umol of AS1 also reduced the rate of phosphate
uptake into renal brush border membrane vesicles and the
expression of NaPi-2 protein detected by Western blotting in
these vesicles. Reversed sequence AS1 was again without effect
on these parameters. These results suggest that systemically
infused oligonucleotides can exert antisense effects in the
renal proximal tubule.
Antisense oligonucleotides offer a potential means to block
expression of individual genes (1-4). The antisense effect of
unmodified oligodeoxynucleotides is limited because they are
rapidly degraded. Several structural modifications have there-
fore been employed to retard oligonucleotide degradation and
thereby increase antisense activity. The modification most
often employed has been the replacement of one oxygen of
each internucleotide linkage with sulfur, which yields a phos-
phorothioate oligonucleotide (2-4). Phosphorothioate oligo-
nucleotides have frequently been shown to exert antisense
activity in cultured cells but have less often been shown to exert
antisense effects in vivo. Antisense activity may be more
difficult to achieve in vivo in part because of limited oligonu-
cleotide uptake by target tissues in living animals. Pharmaco-
dynamic studies suggest, however, that the kidney proximal
tubule could be a particularly suitable target tissue for phos-
phorothioate oligonucleotide antisense treatment in vivo.
These studies have shown that a large portion of systemically
infused phosphorothioate oligonucleotides, which are cleared
rapidly from the circulation, are taken up by the kidney (5-7).
Within the kidney, phosphorothioate oligonucleotides remain
intact for several days and are localized predominantly in the
proximal tubule (6, 7). The current study was designed to
determine whether phosphorothioate oligonucleotides cleared
from the circulation by the kidney could exert antisense effects
in proximal tubule cells. The recently identified rat proximal
tubule sodium phosphate cotransporter, NaPi-2, was selected
as a target for antisense treatment (8, 9). Results showed
suppression of the NaPi-2 message in kidney cortex, along with
reduction of NaPi-2 protein and sodium phosphate cotrans-
port in brush border membrane vesicles from rats that received
a phosphorothioate oligonucleotide designed to hybridize with
NaPi-2 mRNA.
MATERIALS AND METHODS
Oligonucleotides. Experiments were conducted with 18- and
20-mer phosphorothioate oligonucleotides. Three oligonucle-
otides, denoted AS1, AS2, and AS3, were designed to hybridize
with mRNA for NaPi-2 (8). ASI had the sequence 5'-TCC
CCC CAA TCT CTC GCT GT-3' corresponding to positions
64-83 of the NaPi-2 cDNA, AS2 had the sequence 5'-CTC
GCT GTA GGA CAT CAT-3' corresponding to positions
54-71 of the cDNA, and AS3 had the sequence 5'-GCA CCC
ACA ATG AGT CCT-3' corresponding to positions 31-48 of
the cDNA. Target sequences were in each case close to the
presumed translation initiation site (positions 54-59). A
scrambled sequence of AS1, 5'-CTC ACA CCT TGC GCT
CTC CT-3', and the reversed sequence ofAS1 (rASI), 5'-TGT
CGC TCT CTA ACC CCC CT-3', were used as controls.
Oligonucleotides were prepared using amidite chemistry and
obtained commercially (Oligos Etc., Willsonville, OR).
Treatment of Rats with Oligonucleotides. Oligonucleotides
were given to male Sprague-Dawley rats weighing 270-330 g.
Rats were placed on a low phosphate diet (0.07% phosphorus;
Teklad, Madison, WI) for 3 days before oligonucleotide ad-
ministration. They were then anesthetized with Brevital (Eli
Lilly; 50 mg/kg intraperitoneally) and maintained on a tem-
perature-regulated table while a single dose of oligonucleotide
dissolved in 3 ml of 0.9% NaCl was infused into the right
jugular vein over 2 hr. Control rats received saline alone.
Following oligonucleotide or saline administration, rats were
continued on the low phosphate diet for an additional 3 days.
They were then anesthetized with Inactin (100 mg/kg intra-
peritoneally), and kidney tissue was obtained for Northern
analyses, Western analyses, and brush border membrane ves-
icle transport studies. Additional Northern analyses were
carried out in a group of rats that were maintained on normal
laboratory chow (1.0% phosphorus) and received a control
saline infusion.
Northern Analysis. Total RNA (- 15 ,ug) from whole kidneys
was denatured, electrophoresed on 1% agarose/formaldehyde
gels, and transferred to nylon membranes by vacuum blotting.
The membranes were exposed to UV light for 2 min to crosslink
the RNA. Full-length cDNA probes for NaPi-2 (8) and cyclo-
philin (10) were random primer-labeled using [a-32P]dCTP
(GIBCO/BRL kit, Gaithersburg, MD). Blots were prehybridized
and then hybridized for 12 hr at 65°C in buffer containing 0.5 M
sodium phosphate (pH 7.2), 7% SDS, and 1 mM EDTA. Blots
were then washed once at room temperature and twice at
hybridization temperature in high stringency buffer (5% SDS/1 x
SSC) and analyzed by exposure to x-ray films and densitometry
Abbreviation: rASI, the reversed sequence of AS1.
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(Ultrascan Laser; LKB) or by Phosphorlmager (model 445 SI;
Molecular Dynamics).
Western Analysis. Brush border membrane vesicles were
prepared from kidney cortex using the MgCl2 precipitation
method (11). Samples of these vesicles were subjected to
Western analysis. SDS/PAGE was performed as described by
Laemmli (12) using 9% acrylamide gels. Before electrophore-
sis, samples were diluted in buffer (8% SDS/4 mM EDTA/
40% glycerol/0.38 M Tris-HCl, pH 6.8/0.1% bromophenol
blue), and proteins were denatured by boiling for 2 min.
Electrophoretic transfer to nitrocellulose membranes (Schlei-
cher & Schuell) was performed as described by Towbin et al.
(13). Membranes were then blocked for 2 hr at room temper-
ature [(5% milk powder/1% Triton X-100/Tris-buffered sa-
line (TBS; 25 mM Tris-HCl, pH 7.4/150 mM NaCl)] and
incubated overnight with polyclonal antisera directed against
a synthetic COOH-terminal peptide of NaPi-2 at a dilution of
1:4000 (9). Control studies were done with a rabbit antibody
against calf alkaline phosphatase (Dako) and a rabbit antibody
against keratin 8 (14). Binding of the primary antibodies was
detected using a peroxidase-conjugated goat anti-rabbit IgG
(Sigma), followed by application of a chemiluminescence
detection system (ECL; Amersham) and exposure to x-ray
film.
Brush Border Membrane Vesicle Transport. The transport
of [32P]phosphate (0.1 mM) and [35S]sulfate (0.1 mM) into
isolated brush border membrane vehicles was measured in
triplicate in the presence of 100 mM mannitol, 10 mM
Tris-Hepes (pH 7.4), and either 100 mM KCl or 100 mM NaCl
as described by Brown et al. (15). The sodium-dependent
component of transport was calculated as the difference in
transport in the presence of NaCl and KCl.
Statistics. Experimental groups for Western analyses and
brush border membrane transport studies each included four
saline-infused control rats and four oligonucleotide-infused
rats. Experimental groups for Northern analyses included
three to six control rats and three to six oligonucleotide-infused
rats. Values are presented as the mean ± SD. The unpaired t
test was used to assess the significance of differences in
experiments containing two groups, and ANOVA and Fisch-
er's exact test were used to assess the significance of differences
in experiments containing more than two groups.
RESULTS
The effects of systemic infusion of oligonucleotides on renal
expression of the message for NaPi-2 are depicted in Figs. 1
and 2. Experiments were performed first with 2.5-,umol doses
of oligonucleotides. Densitometric analysis showed that at this
dose, oligonucleotide AS1 reduced the NaPi-2 mRNA to
cyclophilin mRNA ratio by an average of 40% ± 17%. This
overall result was obtained in three separate experiments in
which the NaPi-2 to cyclophilin mRNA ratio was reduced by
46% ± 10%, 42% ± 19%, and 29% ± 25%, respectively. In
contrast, rAS1 and a scrambled sequence of AS1 did not affect
renal NaPi-2 mRNA levels. NaPi-2 mRNA levels were likewise
not significantly reduced by 2.5 ,tmol of the antisense oligo-
nucleotides AS2 and AS3 (data not shown). The NaPi-2
mRNA to cyclophilin mRNA ratio was, however, lower in a
group of rats maintained on normal chow than in control rats
maintained on the low phosphorus diet, as has been described
(16). Administration of an increased dose of 7.5 ,tmol of AS1
reduced the NaPi-2 to cyclophilin mRNA ratio by 46% ± 21%,
whereas infusion of an equal dose of rAS1 had no effect.
Systemic infusion of oligonucleotides had no effect on body
weight, which remained stable (preinfusion, 289 ± 22 g;
postinfusion, 289 ± 19 g) between oligonucleotide adminis-
tration and sacrifice and was not different in oligonucleotide-
and saline-infused rats.
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FIG. 1. NaPi-2 to cyclophilin message ratios in the kidneys of rats
after oligonucleotide treatment, expressed as a percent of the control
ratio observed in rats receiving saline. A 2.5-,umol dose ofAS1 reduced
the NaPi-2 to cyclophilin mRNA ratio by 41% ± 17% (mean of three
separate experiments in which three, six, and five rats received AS1 and
an equal number of rats received saline). Similar doses of rAS1 and
scrambled ASl (sAS1) had no effect (separate experiments in which
five rats received oligonucleotides and five rats received saline). A
7.5-j,mol dose of AS1 also reduced the NaPi-2 to cyclophilin mRNA
ratio, whereas rAS1 in this dose again had no effect (separate
experiments in which five rats received oligonucleotides and five rats
received saline). As compared with rats maintained on a low phos-
phorus diet, the NaPi-2 to cyclophilin mRNA ratio was also reduced
in rats maintained on normal chow (NC), which received no oligonu-
cleotide [n = fourNC rats versus six control rats on the low phosphorus
diet; *, P < 0.05 vs. simultaneous control (assigned 100%)].
Western analysis of brush border membrane proteins ob-
tained from rats receiving 7.5 ,umol of oligonucleotides is
illustrated in Fig. 3. In two separate experiments, densitometry
showed that AS1 reduced staining of the 85-kDa protein that
is recognized by antibody raised against NaPi-2 peptide by 60%
± 19% and by 84% ± 20% (both P < 0.05; overall mean
reduction 72% ± 20%). By contrast, a 7.5-,tmol dose of AS1
had no effect on the amount of alkaline phosphatase or keratin
8 in brush border membranes (Fig. 3), and an equal dose of
rAS1 had no effect on the 85-kDa protein recognized by
antibody against NaPi-2 peptide (data not shown). Statistically
significant reduction in the 85-kDa protein was not observed
in vesicles from rats that received 2.5 ,umol of AS1 (57% ±
30% of control, P > 0.05).
The time course of phosphate uptake by brush border
membrane vesicles from rats that received 7.5 ,umol of oligo-
nucleotides is depicted in Fig. 4. The initial rate of phosphate
uptake was reduced in rats receiving 7.5 ,umol of AS1 but not
altered in rats receiving an equal amount of rAS1. Vesicle
uptake of sulfate, in contrast to phosphate, was not affected by
administration of either AS1 or rAS1. Studies using the same
techniques did not reveal a reduction in phosphate uptake by
C C AS AS C C rAS rAS
NaPi-2
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FIG. 2. Sample Northern analysis of NaPi-2 message expression in
rats receiving 2.5 ,umol of oligonucleotides. In comparison with saline
infusion in simultaneously prepared control rats (C), AS1 reduced
NaPi-2 message expression, whereas rAS1 had no effect.
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FIG. 3. Western analysis of brush border membrane proteins in rats
receiving 7.5 ,umol of oligonucleotides. In comparison with saline infusion
in simultaneously prepared control rats (C), AS1 reduced the expression
of 85-kDa protein detected by a polyclonal antibody raised against a
peptide sequence of NaPi-2 (9), but it had no effect on proteins detected
by antisera against alkaline phosphatase and keratin 8.
brush border membrane vesicles from rats that received 2.5
,umol of AS1 (data not shown).
DISCUSSION
Effective use of antisense oligonucleotides in vivo has been
limited in part because it is difficult to achieve adequate
cellular uptake of oligonucleotides in target tissues. To date,
the most extensive studies of antisense therapy in vivo have
been performed in the rat carotid restenosis model (4, 17, 18).
In this model, genes promoting vascular growth have been
suppressed by local application of antisense oligonucleotides
incorporated into gels or into liposomes containing viral
proteins to increase tissue uptake. Following parenteral ad-
ministration without special preparation to facilitate tissue
uptake, phosphorothioate oligonucleotides have been shown
to block increased expression of genes associated with malig-
nant cell proliferation and to retard tumor growth in mice (4,
19). A single study has demonstrated suppression of a normal,
constituitively expressed host gene following parenteral anti-
sense treatment (20). This study demonstrated reduction in
hepatic expression of PKC-a in mice receiving intraperitoneal
injections of a 20-mer phosphorothioate oligonucleotide.
The present study sought to show whether a systemically
infused phosphorothioate oligonucleotide could exert anti-
sense effects in the renal proximal tubule. Pharmacodynamic
studies have shown that phosphorothioate oligonucleotides are
taken up by the kidney in large quantity following systemic
infusion and remain intact in kidney cells over several days
(5-7). Autoradiographic studies by the authors have shown
further that phosphorothioate oligonucleotides taken up by the
kidney are localized predominantly in the proximal tubule (7).
3- 0 Control
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Other recent studies suggest that proximal tubule cells possess
a specific transport mechanism for uptake of oligonucleotides
from the tubule lumen (21). Together, these studies suggest
that the renal proximal tubule might be a particularly suitable
target for antisense treatment. Studies were therefore per-
formed with antisense targeted against the sodium phosphate
cotransporter NaPi-2. NaPi-2 is known to be localized in the
proximal tubule of the rat and appears to be responsible for a
major portion of tubular phosphate reabsorption in this species
(8, 9, 22) Studies were performed in rats maintained on a low
phosphate diet, as this maneuver has been shown to increase
NaPi-2 expression and sodium phosphate cotransport in the rat
proximal tubule (15, 23).
Results showed suppression of NaPi-2 message expression
by ASI, which was one of three phosphorothioate oligonucle-
otides designed to hybridize with NaPi-2 mRNA. The finding
that gene expression was suppressed by only one of several
potential antisense molecules is in accord with results of
previous studies (20). An advantage of the selection of a
transport molecule as the antisense target in the current study
was that molecular function as well as protein and gene
expression could be assessed. We found that a dose of 7.5 Amol
of AS1 reduced sodium-dependent phosphate uptake and
NaPi-2 protein content in proximal tubule brush border mem-
brane vesicles, and it reduced NaPi-2 message expression as
well. The effect ofAS1 appeared to be dose-dependent, in that
a dose of 2.5 ,umol of AS1 did not significantly reduce
sodium-dependent phosphate uptake or NaPi-2 protein in
vesicles, though it did reduce NaPi-2 message expression. It
should be noted that a direct linear correlation between
message expression and transport protein function may not be
observed in analyses performed at a single time point, as was
the case in the current study. Recent studies suggest, moreover,
that transport may be regulated by shuttling of transporters
between cytoplasmic vesicles and the brush border, and by
synthesis of transport molecules as well, which allows for
further discordance between transport activity and mRNA
levels (24).
Distinguishing suppression of gene expression mediated by
antisense activity from other nonspecific effects of oligonu-
cleotides is a major problem in antisense studies. In the current
study, AS1 reduced membrane vesicle content of NaPi-2
protein but not of alkaline phosphatase or keratin 8. Moreover,
rAS1 did not affect NaPi-2 message expression, NaPi-2 pro-
tein, or vesicle phosphate transport. Together these findings
suggest that the effects of AS1 were attributable to antisense
3
0 0.25 2 4 0 0.25 2 4
TIME (min)
FIG. 4. Uptake of phosphate in brush border membrane vesicles. Closed symbols denote values in rats receiving 7.5 ,umol of oligonucleotides
(AS1, Left; or rAS1, Right), whereas open symbols denote values in simultaneously prepared saline-infused controls. AS1 reduced the rate of
phosphate uptake in membrane vesicles, whereas rAS1 had no effect. (*, P < 0.05 vs. control and rAS1-infused rats; n = four oligonucleotide-infused
rats and four controls in each experiment).
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activity. The finding that AS1 reduced phosphate uptake but
not sulfate uptake into brush border membrane vesicle pro-
vided additional evidence that AS1 caused specific suppression
of NaPi-2 activity and did not cause generalized suppression of
proximal tubule function.
The mechanism by which systemically infused phosphoro-
thioate oligonucleotides enter proximal tubule cells remains to
be identified. Peptides molecules in the size range of oligonu-
cleotides, however, are known to be filtered by the glomerulus,
reabsorbed in the proximal tubule by receptor-mediated en-
docytosis, and then degraded in lysosomes (25). Oligonucle-
otides confined within lysosomes would presumably exert no
antisense effect. Phosphorothioate oligonucleotides are resis-
tant to enzymatic degradation, however, and studies in cul-
tured cells have suggested that they may escape from the
endocytic-lysosomal pathway (26, 27). In addition, the endo-
cytic pathway may not be the only means of phosphorothioate
oligonucleotide entry into cells (26, 28, 29). The current study
does not address these issues but does show that oligonucle-
otides can exert an antisense effect following uptake by
proximal tubule cells. The renal proximal tubule, which takes
up a large portion of systemically infused phosphorothioate
oligonucleotides, may thus be susceptible to antisense treat-
ment.
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